Skip to main content

Table 1 Main characteristics of study population according to regimen started after switch

From: Switching to dual/monotherapy determines an increase in CD8+ in HIV-infected individuals: an observational cohort study

  All study population Triple Dual Mono p value
Patients’ characteristics (n = 1241) (n = 1073) (n = 104) (n = 64)
Male gender, n (%) 988 (79.6%) 853 (79.5%) 86 (82.7%) 49 (76.6%) 0.612
Age, median (IQR) 43 (36–50) 42 (35–50) 45 (38–51) 44 (38–49) 0.065
Mode of HIV transmission, n (%)
 Heterosexual 534 (43.0%) 474 (44.2%) 40 (38.5%) 20 (31.3%) 0.025
 Injection drug use 100 (8.1%) 92 (8.6%) 5 (4.8%) 3 (4.7%)
 Men who have sex with men 533 (42.9%) 440 (41.0%) 54 (51.9%) 39 (60.9%)
 Other/unknown 74 (6.0%) 67 (6.2%) 5 (4.8%) 2 (3.1%)
Migrants, n (%) 151 (12.2%) 136 (12.7%) 8 (7.7%) 7 (10.9%) 0.317
Previous AIDS event, n (%) 161 (130%) 152 (14.2%) 8 (7.7%) 1 (1.6%) 0.004
Years of HIV infection, median (IQR) 3.4 (1.6–6.3) 3.3 (1.6–6.3) 3.3 (1.6–6.5) 4.2 (2.1–6.1) 0.472
HCV Ab, n (%)
 Negative 1057 (85.2%) 908 (84.6%) 88 (84.6%) 61 (95.3%) 0.197
 Positive 120 (9.7%) 109 (10.2%) 10 (9.6%) 1 (1.6%)
 Unknown 64 (5.1%) 56 (5.2%) 6 (5.8%) 2 (3.1%)
CD4 before cART start, n (%)
  < 200 368 (29.7%) 334 (31.1%) 24 (23.1%) 10 (15.6%) 0.047
 201–350 399 (32.2%) 344 (32.1%) 29 (27.9%) 26 (40.6%)
 351–500 307 (24.7%) 258 (24.0%) 30 (28.9%) 19 (29.7%)
 500+ 143 (11.5%) 116 (10.8%) 18 (17.3%) 9 (14.1%)
 Missing 24 (1.9%) 21 (2.0%) 3 (2.8%)
HIV RNA before cART start, n (%)
  < 20,000 337 (27.2%) 279 (26.0%) 37 (35.5%) 21 (32.8%) 0.385
 20,000–100,000 410 (33.0%) 358 (33.3%) 30 (28.9%) 22 (34.4%)
 100,000–250,000 235 (18.9%) 207 (19.3%) 18 (17.3%) 10 (15.6%)
 250,000+ 233 (18.8%) 208 (19.4%) 15 (14.4%) 10 (15.6%)
 Missing 26 (2.1%) 21 (2.0%) 4 (3.9%) 1 (1.6%)
CD4 at switch, median (IQR)
  < 350 219 (17.7%) 199 (18.6%) 14 (13.5%) 6 (9.4%) 0.008
 350–500 285 (23.0%) 255 (23.8%) 23 (22.1%) 7 (10.9%)
 500+ 737 (59.3) 619 (57.6%) 67 (64.4%) 51 (79.7%)
CD4 at switch, median (IQR) 554 (402–740) 547 (394–729) 600 (426–819) 614 (506–807) 0.012
CD8 at switch, median (IQR) 824 (600–1118) 832 (601–1121) 797 (587–1124) 768 (597–1009) 0.467
CD4/CD8 ratio at switch, median (IQR) 0.69 (0.45–0.98) 0.67 (0.44–0.97) 0.78 (0.51–1.10) 0.83 (0.58–1.09) 0.008
CD4/CD8 ratio at switch > = 1, n (%) 303 (24.4%) 256 (23.9%) 29 (27.9%) 18 (28.1%) 0.513
Months of antiretroviral exposure, median (IQR) 18 (9–34) 17 (8–35) 18 (12–36) 20 (12–31) 0.184
Months of viral suppression, median (IQR) 21 (11–39) 21 (10–39) 20 (12–37) 20 (13–34) 0.824
Reason for switch, n (%)
 Toxicity 330 (26.6%) 294 (27.4%) 27 (26.0%) 9 (14.1%) < 0.001
 Simplification 493 (39.6%) 407 (38.0%) 42 (40.4%) 44 (68.7%)
 Patient’s decision 18 (1.5%) 17 (1.6%) 0 (0.0%) 1 (1.6%)
 Other 387 (31.2%) 346 (32.2%) 31 (29.8%) 10 (15.6%)
 Missing 13 (1.1%) 9 (0.8%) 4 (3.8%) 0 (0.0%)